vedolizumab,erdafitinib
janssen,takeda
[' vedo', 'ibd', 'erda', 'vedo', 'vedolizumab']
d haens #ecco2023 results of #reprevio trial - #vedo for post op recurrence higher risk cohort immediate post op start (4 weeks) of vedo vs placebo reduced severity of endoscopic recurrence need longer term follow up re clinical recurrence 
IBD clinician& researcher @IBDHull.Chair:Research Committee of @BritSocGastro . Chair of ECCO CLiNCOM. @NIHR (Y&H ) lead. own views ,RT🚫endorse.⚽️ @LFC fan.